Clinical Trials

Latest Headlines

Latest Headlines

Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII

GlaxoSmithKline and Prosensa today conceded defeat in the Phase III study for drisapersen, one of two closely-watched therapies for Duchenne muscular dystrophy which had been vying for the lead in the field. Investigators reported that the therapy failed to significantly improve walking distance in patients.

MorphoSys grabs $126M for clinical trial work

The money will be used, in part, to pay for a mid-stage study of MOR208, its anti-CD19 antibody for chronic lymphocytic leukemia as well as new studies of MOR202, an anti-CD38 antibody currently in a Phase I/IIa clinical trial in multiple myeloma.

GlaxoSmithKline terminates Crohn's drug program following a pivotal failure

When ChemoCentryx reported last month that its Crohn's disease drug vercirnon (GSK1605786) failed   the first of four Phase III trials mounted by GlaxoSmithKline, the biotech said it was awaiting word from the pharma giant on its future development plans.

NovaBay shares jump on positive PhII catheter solution study

Shares of NovaBay Pharmaceuticals shot up 11% after the Emeryville, CA-based biotech said that a mid-stage study of a new solution to prevent problems for people with indwelling urinary catheters proved successful, paving the way for a late-stage trial.

FDA lifts hold on Pluristem's stem cell trial after tweaking protocol

Israel's Pluristem Therapeutics says the FDA has given the company a green light to push ahead on a mid-stage study of one of its stem cell therapies after the agency had finished its review of one patient's severe allergic reaction and tweaked the trial protocol.

Chimerix reports PhII failure for lead antiviral

Investigators tested the antiviral among hematopoietic cell transplant recipients with early adenovirus infection, but said--well into its release--that the therapy fell short on achieving statistical significance on efficacy in the "progression to possible or probable AdV disease or significant changes in AdV viremia.

Neurocrine shares damaged by low-dose drug pratfall in PhIIb

Neurocrine shares took a nasty drubbing after the biotech announced that its low-dose version of an experimental therapy for a rare movement disorder failed a Phase IIb study.

Positive response for Oncolytics' cancer virus program spurs share spike

Shares of Canada's Oncolytics surged again this morning after the biotech reported out a final analysis on its tumor virus Reolysin, showing a 92% response rate among a small group of 25 patients enrolled in a Phase II study.

Biodel stock drops despite positive PhII insulin data

After big gains in its stock price, Biodel shares slipped more than 20% this morning on the back of mid-stage trial results for its fast-acting, mealtime insulin candidate.

Covance teams with Indiana U. for early trials

CRO giant Covance has signed a deal with the Indiana University School of Medicine, bringing more Phase I studies to the school's on-site clinical research unit and giving Covance a broader footprint for early trials.